nach oben

15.05.2024 | Cardiac PET, CT, and MRI (P Cremer, Section Editor)

Assessing Regurgitation Severity, Adverse Remodeling, and Fibrosis with CMR in Primary Mitral Regurgitation

verfasst von: Amr Darwish, Akila Bersali, Mujtaba Saeed, Aneesh Dhore, Dimitrios Maragiannis, K. Carlos El-Tallawi, Dipan J. Shah

Erschienen in: Current Cardiology Reports

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review offers an evidence-based analysis of established and emerging cardiovascular magnetic resonance (CMR) techniques used to assess the severity of primary mitral regurgitation (MR), identify adverse cardiac remodeling and its prognostic effect. The aim is to provide different insights regarding clinical decision-making and enhance the clinical outcomes of patients with MR.

Recent Findings

Cardiac remodeling and myocardial replacement fibrosis are observed frequently in the presence of substantial LV volume overload, particularly in cases with severe primary MR. CMR serves as a useful diagnostic imaging modality in assessing mitral regurgitation severity, early detection of cardiac remodeling, myocardial dysfunction, and myocardial fibrosis, enabling timely intervention before irreversible damage ensues.

Summary

Incorporating myocardial remodeling in terms of left ventricular (LV) dilatation and myocardial fibrosis with quantitative MR severity assessment by CMR may assist in defining optimal timing of intervention.

Nishimura RA, Vahanian A, Eleid MF, Mack MJ. Mitral valve disease–current management and future challenges. Lancet. 2016;387(10025):1324–34. https://doi.org/10.1016/S0140-6736(16)00558-4.CrossRefPubMed

Dziadzko V, Clavel MA, Dziadzko M, et al. Outcome and undertreatment of mitral regurgitation: a community cohort study. Lancet. 2018;391:960–9. https://doi.org/10.1016/S0140-6736(18)30473-2.CrossRefPubMedPubMedCentral

Enriquez-Sarano M, Akins CW, Vahanian A. Mitral regurgitation. Lancet. 2009;373:1382–94. https://doi.org/10.1016/S0140-6736(09)60692-9.CrossRefPubMed

Ling LH, Enriquez-Sarano M, Seward JB, et al. Clinical outcome of mitral regurgitation due to flail leaflet. N Engl J Med. 1996;335:1417–23. https://doi.org/10.1056/NEJM199611073351902.CrossRefPubMed

Grigioni F, Avierinos JF, Ling LH, et al. Atrial fibrillation complicating the course of degenerative mitral regurgitation: determinants and long-term outcome. J Am Coll Cardiol. 2002;40:84–92. https://doi.org/10.1016/s0735-1097(02)01922-8.CrossRefPubMed

Tribouilloy C, Rusinaru D, Grigioni F, et al. Long-term mortality associated with left ventricular dysfunction in mitral regurgitation due to flail leaflets: a multicenter analysis. Circ Cardiovasc Imaging. 2014;7:363–70. https://doi.org/10.1161/CIRCIMAGING.113.001251.CrossRefPubMed

Rossi A, Dini FL, Faggiano P, et al. Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy. Heart. 2011;97:1675–80. https://doi.org/10.1136/hrt.2011.225789.CrossRefPubMed

Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med. 2005;352:875–83. https://doi.org/10.1056/NEJMoa041451.CrossRefPubMed

Filsoufi F, Carpentier A. Principles of reconstructive surgery in degenerative mitral valve disease. Semin Thorac Cardiovasc Surg. 2007;19:103–10. https://doi.org/10.1053/j.semtcvs.2007.04.003.CrossRefPubMed

10.

Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, Bonny A, Brauer M, Brodmann M, Cahill TJ, Carapetis J, Catapano AL, Chugh SS, Cooper LT, Coresh J, Criqui M, DeCleene N, Eagle KA, Emmons-Bell S, Feigin VL, Fernández-Solà J, Fowkes G, Gakidou E, Grundy SM, He FJ, Howard G, Hu F, Inker L, Karthikeyan G, Kassebaum N, Koroshetz W, Lavie C, Lloyd-Jones D, Lu HS, Mirijello A, Temesgen AM, Mokdad A, Moran AE, Muntner P, Narula J, Neal B, Ntsekhe M, Moraes de Oliveira G, Otto C, Owolabi M, Pratt M, Rajagopalan S, Reitsma M, Ribeiro ALP, Rigotti N, Rodgers A, Sable C, Shakil S, Sliwa-Hahnle K, Stark B, Sundström J, Timpel P, Tleyjeh IM, Valgimigli M, Vos T, Whelton PK, Yacoub M, Zuhlke L, Murray C, Fuster V; GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982–3021. https://doi.org/10.1016/j.jacc.2020.11.010. Erratum in: J Am Coll Cardiol. 2021 Apr 20;77(15):1958–1959. PMID: 33309175; PMCID: PMC7755038.

11.

Han YC, Peters DC, Salton CJ, Bzymek D, Nezafat R, Goddu B, et al. Cardiovascular magnetic resonance characterization of mitral valve prolapse. JACC Cardiovasc Imaging. 2008;1:294–303. https://doi.org/10.1016/j.jcmg.2008.01.013.CrossRefPubMed

12.

Basso C, Perazzolo Marra M, Rizzo S, De Lazzari M, Giorgi B, Cipriani A, et al. Arrhythmic mitral valve prolapse and sudden cardiac death. Circulation. 2015;132:556–66. https://doi.org/10.1161/CIRCULATIONAHA.115.016291.CrossRefPubMed

13.

Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease The task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017;38:2739. https://doi.org/10.1093/eurheartj/ehx391.CrossRefPubMed

14.

Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, et al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr. 2017;30:303–71. https://doi.org/10.1016/j.echo.2017.01.007.CrossRefPubMed

15.

Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, O'Gara PT, Rigolin VH, Sundt TM 3rd, Thompson A, Toly C; ACC/AHA Joint Committee Members; O'Gara PT, Beckman JA, Levine GN, Al-Khatib SM, Armbruster A, Birtcher KK, Ciggaroa J, Deswal A, Dixon DL, Fleisher LA, de Las Fuentes L, Gentile F, Goldberger ZD, Gorenek B, Haynes N, Hernandez AF, Hlatky MA, Joglar JA, Jones WS, Marine JE, Mark D, Palaniappan L, Piano MR, Spatz ES, Tamis-Holland J, Wijeysundera DN, Woo YJ. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Thorac Cardiovasc Surg. 2021;162(2):e183–e353. https://doi.org/10.1016/j.jtcvs.2021.04.002.

16.

Pennell DJ, Sechtem UP, Higgins CB, et al. Clinical indications for cardiovascular magnetic resonance (CMR): consensus panel report. Eur Heart J. 2004;25:1940–65. https://doi.org/10.1016/j.ehj.2004.06.040.CrossRefPubMed

17.

Masci PG, Dymarkowski S, Bogaert J. Valvular heart disease: what does cardiovascular MRI add? Eur Radiol. 2008;18:187–208. https://doi.org/10.1007/s00330-007-0731-x.CrossRef

18.

Cawley PJ, Maki JH, Otto CM. Cardiovascular magnetic resonance imaging for valvular heart disease: technique and validation. Circulation. 2009;119:468–78. https://doi.org/10.1161/CIRCULATIONAHA.107.742486.CrossRefPubMed

19.

Nayak KS, Nielsen JF, Bernstein MA, et al. Cardiovascular magnetic resonance phase contrast imaging. J Cardiovasc Magn Reson. 2015;17:71. https://doi.org/10.1186/s12968-015-0172-7.CrossRefPubMedPubMedCentral

20.

Myerson SG, d’Arcy J, Christiansen JP, Dobson LE, Mohiaddin R, Francis JM, Prendergast B, Greenwood JP, Karamitsos TD, Neubauer S. Determination of Clinical Outcome in Mitral Regurgitation With Cardiovascular Magnetic Resonance Quantification. Circulation. 2016;133(23):2287–96. https://doi.org/10.1161/CIRCULATIONAHA.115.017888.CrossRefPubMed

21.

Buchner S, Debl K, Poschenrieder F, et al. Cardiovascular magnetic resonance for direct assessment of anatomic regurgitant orifice in mitral regurgitation. Circ Cardiovasc Imaging. 2008;1:148–55. https://doi.org/10.1161/CIRCIMAGING.107.753103.CrossRefPubMed

22.

Chan KMJ, Wage R, Symmonds K, Rahman-Haley S, Mohiaddin RH, Firmin DN, et al. Towards comprehensive assessment of mitral regurgitation using cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10:61. https://doi.org/10.1186/1532-429X-10-61.CrossRefPubMedPubMedCentral

23.

Gabriel RS, Kerr AJ, Raffel OC, Stewart RA, Cowan BR, Occleshaw CJ. Mapping of mitral regurgitant defects by cardiovascular magnetic resonance in moderate or severe mitral regurgitation secondary to mitral valve prolapse. J Cardiovasc Magn Reson. 2008;10:16. https://doi.org/10.1186/1532-429X-10-16.CrossRefPubMedPubMedCentral

24.

Wolff R, Uretsky S. Defining the left ventricular base in mitral valve prolapse: impact on systolic function and regurgitation. Int J Cardiovasc Imaging. 2020;36:2221–7. https://doi.org/10.1007/s10554-020-01927-0.CrossRefPubMed

25.

Hudsmith LE, Petersen SE, Francis JM, Robson MD, Neubauer S. Normal human left and right ventricular and left atrial dimensions using steady state free precession magnetic resonance imaging. J Cardiovasc Magn Reson. 2005;7:775–82. https://doi.org/10.1080/10976640500295516.CrossRefPubMed

26.

Penicka M, Vecera J, Mirica DC, Kotrc M, Kockova R, Van Camp G. Prognostic implications of magnetic resonance-derived quantification in asymptomatic patients with organic mitral regurgitation: comparison with Doppler echocardiography-derived integrative approach. Circulation. 2018;137:1349–60. https://doi.org/10.1161/CIRCULATIONAHA.117.029332.CrossRefPubMed

27.

Romero Daza A, Chokshi A, Pardo P, Maneiro N, Guijarro Contreras A, Larrañaga-Moreira JM, et al. Mitral valve prolapse morphofunctional features by cardiovascular magnetic resonance: more than just a valvular disease. J Cardiovasc Magn Reson. 2021;23:107. https://doi.org/10.1186/s12968-021-00800-w.CrossRefPubMedPubMedCentral

28.

Cameli M, Lisi M, Righini FM, Massoni A, Natali BM, Focardi M, et al. Usefulness of atrial deformation analysis to predict left atrial fibrosis and endocardial thickness in patients undergoing mitral valve operations for severe mitral regurgitation secondary to mitral valve prolapse. Am J Cardiol. 2013;111(4):595–601. https://doi.org/10.1016/j.amjcard.2012.10.049.CrossRefPubMed

29.

El-Tallawi KC, Kitkungvan D, Xu J, Cristini V, Yang EY, Quinones MA, et al. Resolving the disproportionate left ventricular enlargement in mitral valve prolapse due to barlow disease: insights from cardiovascular magnetic resonance. JACC Cardiovasc Imaging. 2021;14:573–84. https://doi.org/10.1016/j.jcmg.2020.08.029.CrossRefPubMed

30.

Levy F, Iacuzio L, Marechaux S, Civaia F, Dommerc C, Wautot F, et al. Influence of prolapse volume in mitral valve prolapse. Am J Cardiol. 2021;157:64–70. https://doi.org/10.1016/j.amjcard.2021.07.019.CrossRefPubMed

31.

Ahmed MI, Andrikopoulou E, Zheng J, Ulasova E, Pat B, Kelley EE, Powell PC, Denney TS Jr, Lewis C, Davies JE, Darley-Usmar V, Dell’Italia LJ. Interstitial Collagen Loss, Myocardial Remodeling, and Function in Primary Mitral Regurgitation. JACC Basic Transl Sci. 2022;7(10):973–81. https://doi.org/10.1016/j.jacbts.2022.04.014.CrossRefPubMedPubMedCentral

32.

Croisille P, Revel D, Saeed M. Contrast agents and cardiac MR imaging of myocardial ischemia: from bench to bedside. Eur Radiol. 2006;16:1951–63. https://doi.org/10.1007/s00330-006-0244-z.CrossRefPubMed

33.

Holtackers RJ, Van De Heyning CM, Chiribiri A, et al. Dark-blood late gadolinium enhancement cardiovascular magnetic resonance for improved detection of subendocardial scar: a review of current techniques. J Cardiovasc Magn Reson. 2021;23:96. https://doi.org/10.1186/s12968-021-00777-6.CrossRefPubMedPubMedCentral

34.

Van De Heyning CM, Holtackers RJ, Nazir MS, Grapsa J, Demetrescu C, Pype L, et al. Dark-blood late gadolinium enhancement CMR improves detection of papillary muscle fibrosis in patients with mitral valve prolapse. Eur J Radiol. 2022;147: 110118. https://doi.org/10.1016/j.ejrad.2021.110118.CrossRefPubMed

35.

Kim, et al. Flow-Independent Dark-blood DeLayed Enhancement (FIDDLE): validation of a novel black blood technique for the diagnosis of myocardial infarction. J Cardiovasc Magn Reson. 2016;18(Suppl 1). https://doi.org/10.1186/1532-429X-18-S1-O55.

36.

•• Kitkungvan D, Nabi F, Kim RJ, Bonow RO, Khan MA, Xu J, et al. Myocardial fibrosis in patients with primary mitral regurgitation with and without prolapse. J Am Coll Cardiol. 2018;72:823–34. https://doi.org/10.1016/j.jacc.2018.06.048. Findings from this study showed higher prevalence of LV fibrosis in patients with MVP compared to those without MVP and LV fibrosis may represent a risk marker for cardiac events.CrossRefPubMed

37.

•• Constant Dit Beaufils A-L, Huttin O, Jobbe-Duval A, Senage T, Filippetti L, Piriou N, et al. Replacement myocardial fibrosis in patients with mitral valve prolapse: relation to mitral regurgitation, ventricular remodeling, and arrhythmia. Circulation. 2021;143:1763–74. https://doi.org/10.1161/CIRCULATIONAHA.120.050214. This study showed that replacement myocardial fibrosis detected by LGE on CMR was independently associated with an increase in cardiovascular events (cardiac death, HF, new-onset AF, arterial embolism, and life-threatening ventricular arrhythmia) during follow-up reinforcing the prognostic interest of CMR in MVP/MR.CrossRefPubMed

38.

Nagata Y, Bertrand PB, Baliyan V, Kochav J, Kagan RD, Ujka K, Alfraidi H, van Kampen A, Morningstar JE, Dal-Bianco JP, Melnitchouk S, Holmvang G, Borger MA, Moore R, Hua L, Sultana R, Calle PV, Yum B, Guerrero JL, Neilan TG, Picard MH, Kim J, Delling FN, Hung J, Norris RA, Weinsaft JW, Levine RA. Abnormal Mechanics Relate to Myocardial Fibrosis and Ventricular Arrhythmias in Patients With Mitral Valve Prolapse. Circ Cardiovasc Imaging. 2023;16(4):e014963. https://doi.org/10.1161/CIRCIMAGING.122.014963.CrossRefPubMed

39.

Figliozzi S, Georgiopoulos G, Lopes PM, Bauer KB, Moura-Ferreira S, Tondi L, et al. Myocardial fibrosis at cardiac mri helps predict adverse clinical outcome in patients with mitral valve prolapse. Radiology. 2022;306:112–21. https://doi.org/10.1148/radiol.220454.CrossRefPubMed

40.

De Meester de Ravenstein C, Bouzin C, Lazam S, Boulif J, Amzulescu M, Melchior J, et al. Histological Validation of measurement of diffuse interstitial myocardial fibrosis by myocardial extravascular volume fraction from Modified Look-Locker imaging (MOLLI) T1 mapping at 3 T. J Cardiovasc Magn Reson. 2015;17:48. https://doi.org/10.1186/s12968-015-0150-0.

41.

Fontana M, White SK, Banypersad SM, Sado DM, Maestrini V, Flett AS, et al. Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR. J Cardiovasc Magn Reson. 2012;14:88. https://doi.org/10.1186/1532-429X-14-88.

42.

Kramer CM, Barkhausen J, Bucciarelli-Ducci C, Flamm SD, Kim RJ, Nagel E. Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update. J Cardiovasc Magn Reson. 2020;22:17. https://doi.org/10.1186/s12968-020-00607-1.CrossRefPubMedPubMedCentral

43.

Treibel TA, Fontana M, Maestrini V, Castelletti S, Rosmini S, Simpson J, et al. Automatic measurement of the myocardial interstitium: synthetic extracellular volume quantification without hematocrit sampling. JACC Cardiovasc Imaging. 2016;9:54–63. https://doi.org/10.1016/j.jcmg.2015.11.008.CrossRefPubMed

44.

• Kitkungvan D, Yang EY, El Tallawi KC, Nagueh SF, Nabi F, Khan MA, et al. Extracellular volume in primary mitral regurgitation. JACC Cardiovasc Imaging. 2021;14:1146–60. https://doi.org/10.1016/j.jcmg.2020.10.010. Findings of this study showed that diffuse interstitial fibrosis as inferred by ECV was associated with MR severity, regardless of primary MR etiology and that ECV was independently associated with symptoms related to MR and clinical events.CrossRefPubMed

45.

Kitkungvan D, Yang EY, El Tallawi KC, Nagueh SF, Nabi F, Khan MA, et al. Prognostic implications of diffuse interstitial fibrosis in asymptomatic primary mitral regurgitation. Circulation. 2019;140:2122–4. https://doi.org/10.1161/CIRCULATIONAHA.119.043250.CrossRefPubMedPubMedCentral

46.

Liu B, Neil DAH, Bhabra M, Patel R, Barker TA, Nikolaidis N, et al. Reverse myocardial remodeling following valve repair in patients with chronic severe primary degenerative mitral regurgitation. JACC Cardiovasc Imaging. 2022;15:224–36. https://doi.org/10.1016/j.jcmg.2021.07.007.CrossRefPubMed

47.

el Ibrahim SH. Myocardial tagging by cardiovascular magnetic resonance: evolution of techniques–pulse sequences, analysis algorithms, and applications. J Cardiovasc Magn Reson. 2011;13:36. https://doi.org/10.1186/1532-429x-13-36.CrossRefPubMedPubMedCentral

48.

Williams LK, Forero JF, Popovic ZB, Phelan D, Delgado D, Rakowski H, Wintersperger BJ, Thavendiranathan P. Patterns of CMR measured longitudinal strain and its association with late gadolinium enhancement in patients with cardiac amyloidosis and its mimics. J Cardiovasc Magn Reson. 2017;19(1):61. https://doi.org/10.1186/s12968-017-0376-0.CrossRefPubMedPubMedCentral

49.

Pedrizzetti G, Claus P, Kilner PJ, Nagel E. Principles of cardiovascular magnetic resonance feature tracking and echocardiographic speckle tracking for informed clinical use. J Cardiovasc Magn Reson. 2016;18:51. https://doi.org/10.1186/s12968-016-0269-7.CrossRefPubMedPubMedCentral

50.

Schuster A, Hor KN, Kowallick JT, Beerbaum P, Kutty S. Cardiovascular magnetic resonance myocardial feature tracking: concepts and clinical applications. Circ Cardiovasc Imaging. 2016;9:e004077. https://doi.org/10.1161/circimaging.115.004077.CrossRefPubMed

51.

Padiyath A, Gribben P, Abraham JR, et al. Echocardiography and cardiac magnetic resonance-based feature tracking in the assessment of myocardial mechanics in tetralogy of Fallot: an intermodality comparison. Echocardiography. 2013;30:203–10. https://doi.org/10.1111/echo.12016.CrossRefPubMed

52.

Morton G, Schuster A, Jogiya R, Kutty S, Beerbaum P, Nagel E. Inter-study reproducibility of cardiovascular magnetic resonance myocardial feature tracking. J Cardiovasc Magn Reson. 2012;14:43. https://doi.org/10.1186/1532-429x-14-43.CrossRefPubMedPubMedCentral

53.

Augustine D, Lewandowski AJ, Lazdam M, et al. Global and regional left ventricular myocardial deformation measures by magnetic resonance feature tracking in healthy volunteers: comparison with tagging and relevance of gender. J Cardiovasc Magn Reson. 2013;15:8. https://doi.org/10.1186/1532-429x-15-8.CrossRefPubMedPubMedCentral

Titel: Assessing Regurgitation Severity, Adverse Remodeling, and Fibrosis with CMR in Primary Mitral Regurgitation
verfasst von: Amr Darwish
Akila Bersali
Mujtaba Saeed
Aneesh Dhore
Dimitrios Maragiannis
K. Carlos El-Tallawi
Dipan J. Shah
Publikationsdatum: 15.05.2024
Verlag: Springer US
Erschienen in: Current Cardiology Reports
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-024-02069-8

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Assessing Regurgitation Severity, Adverse Remodeling, and Fibrosis with CMR in Primary Mitral Regurgitation

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie